 |
市場調查報告書
商品編碼
1461459
納洛酮市場：按實力、給藥途徑、分銷管道和地區分類Naloxone Market, By Strength, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
納洛酮市場規模預計到2024年為13.415億美元，預計到2031年將達到26.839億美元，2024年至2031年的年複合成長率（CAGR）為10.4%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2023/2024年市場規模 | 13.415 億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測期間 2023/2024 至 2030/2031 年年複合成長率 | 10.40% | 2030/2031 年預計金額 | 26.839 億美元 |
納洛酮市場佔有率(%)，按地區分類，2024 年
納洛酮是一種鴉片類藥物拮抗，用於完全或部分逆轉鴉片類藥物過量攝取。它的作用是競爭性地結合鴉片受體並逆轉或阻斷其他鴉片類藥物的作用。納洛酮已成為鴉片類藥物過量攝取緊急醫療護理的重要組成部分。世界許多地區持續存在鴉片類藥物危機，近年來鴉片類藥物濫用的盛行率迅速增加。因此，對用於緊急治療的現成納洛酮製劑的需求不斷成長。預計這一因素將對未來幾年全球納洛酮市場的成長軌跡產生重大影響。
市場動態：
全球納洛酮市場主要是由全球鴉片類藥物過量攝取案例的增加所推動的。根據美國藥物濫用研究所的數據，2000 年至 2019 年間，美國鴉片類藥物過量攝取死亡率增加了 130% 以上。此外，COVID-19 大流行進一步加劇了社會隔離對心理健康的影響，並增加了許多國家鴉片類藥物的濫用。醫療和執法機構對滴鼻劑和自動注射器等易於使用的納洛酮輸送製劑的高需求正在推動市場成長。然而，與納洛酮療法相關的副作用和替代治療方案的可用性限制了市場的擴張。持續研究和開發長效納洛酮製劑為主要企業提供了利潤豐厚的未來機會。
本研究的主要特點
- 本報告詳細分析了全球納洛酮市場，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
- 它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球納洛酮市場的主要企業。
- 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 本研究報告針對該產業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 透過用於分析全球納洛酮市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目標
- 先決條件
- 簡稱
第2章 市場概況
- 報告說明
- 市場定義和範圍
- 執行摘要
- 一致的機會地圖 (COM)
第3章市場動態、法規及趨勢分析
- 市場動態
- 影響分析
- 波特的分析
- 產業動態
- 流行病學
- 贖回場景
- 監管場景
- 產品上市及核准
- 收購和協作場景
第4章全球納洛酮市場－冠狀病毒 (COVID-19) 大流行的影響
- COVID-19 流行病學
- COVID-19 對納洛酮需求和供應的影響
- COVID-19 對整個醫療產業的影響
第5章 全球納洛酮市場，依實力分類，2019-2031 年（百萬美元）
第6章 全球納洛酮市場，依途徑，2019-2031 年（百萬美元）
- 介紹
- 鼻內
- 注射
- 肌肉注射
- 皮下的
- 靜脈
第 7 章 全球納洛酮市場，依通路分類，2019-2031 年（百萬美元）
- 介紹
- 醫院藥房
- 零售藥房
- 網路藥房
第8章全球納洛酮市場，按地區，2019-2031（百萬美元）
- 介紹
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 東南亞國協
- 其他亞太地區
- 波灣合作理事會
- 以色列
- 其他中東地區
- 非洲
- 南非
- 中部非洲
- 北非
第9章 競爭格局
- 公司簡介
- Viatris Inc.
- Opiant Pharmaceuticals
- Akorn Operating Company LLC
- Pfizer, Inc.
- Novartis AG
- Indivior Plc.
- Emergent BioSolutions Inc.
- Amphastar Pharmaceuticals, Inc.
- Kern Pharma, SL
- Hikma Pharmaceuticals PLC
- Mundipharma International Limited
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
第10章分析師的觀點
- 升起和降落
- 綜合機會圖
第11章 參考文獻與調查方法
- 參考
- 調查方法
簡介目錄
Product Code: CMI1804
The naloxone market is estimated to be valued at USD 1,341.5 Mn in 2024 and is expected to reach USD 2,683.9 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2023/2024: | US$ 1,341.5 Mn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 10.40% | 2030/2031 Value Projection: | US$ 2,683.9 Mn |
Naloxone Market Share (%), By Region, 2024
Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.
Market Dynamics:
The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2019. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.
Key Features of the Study:
- This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.
Market Segmentation
- Strength:
- 2.0 mg/ml
- 1 mg/ml
- 0.4 mg/ml
- Others
- Route of Administration:
- Intranasal
- Injectable
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- EMERGENT
- Indivior PLC
- Akorn, Inc
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Sandoz
- Teva Pharmaceuticals
- Amphastar Pharmaceuticals, Inc.
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Naloxone Market, By Strength
- Naloxone Market, By Route of Administration
- Naloxone Market, By Distribution Channel
- Naloxone Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Porter's Analysis
- Industry Trends
- Key Highlights
- Epidemiology
- Reimbursement Scenario
- Regulatory Scenario
- Product Launch and Approvals
- Acquisition and Collaboration Scenario
4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on the Demand and Supply of Naloxone
- Impact of COVID-19 on the Overall Healthcare Sector
5. Global Naloxone Market, By Strength, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- 2.0 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- 1mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- 0.4 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
6. Global Naloxone Market, By Route of Administration, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Intramuscular
- Subcutaneous
- Intravenous
7. Global Naloxone Market, By Distribution Channel, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
8. Global Naloxone Market, By Region, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019-2031
- Regional Trends
- North America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country/Region, 2019-2031 (USD MN)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- Viatris Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Opiant Pharmaceuticals
- Akorn Operating Company LLC
- Pfizer, Inc.
- Novartis AG
- Indivior Plc.
- Emergent BioSolutions Inc.
- Amphastar Pharmaceuticals, Inc.
- Kern Pharma, S.L.
- Hikma Pharmaceuticals PLC
- Mundipharma International Limited
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
